Vital Therapies reported $4.07M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Biomarin Pharmaceutical BMRN:US $ 196.83M 2.22M
Dynavax Technologies DVAX:US $ 35.74M 4.27M
Enanta Pharmaceuticals ENTA:US $ 12.93M 2.45M
Epizyme EPZM:US $ 24.11M 3.09M
Insmed INSM:US $ 59.97M 3.23M
Intercept Pharmaceuticals ICPT:US $ 39.98M 10.02M
Mirati Therapeutics MRTX:US $ 54.23M 277K
Omeros OMER:US $ 13.92M 2.96M
Orasure Technologies OSUR:US $ 29.26M 2.61M
Regulus Therapeutics RGLS:US $ 2.47M 423K
Revance Therapeutics RVNC:US $ 46.19M 2.21M
Ultragenyx Pharmaceutical RARE:US $ 68.14M 825K
United Therapeutics UTHR:US $ 141.5M 62.5M
Vital Therapies VTL:US $ 4.07M 82K
Xoma XOMA:US $ 5.71M 594K